Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIPO NASDAQ:PBLA NASDAQ:SRNE NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIPOLipella Pharmaceuticals$0.60+1.7%$0.68$0.55▼$7.31$2.73M-0.1832,908 shs615 shsPBLAPanbela Therapeutics$0.15$0.17$0.01▼$0.47$728K1.3316,136 shsN/ASRNESorrento Therapeutics$0.00+2.8%$0.00$0.00▼$0.10$1.99M1.08122,404 shs36,874 shsVRAXVirax Biolabs Group$0.57-6.9%$0.81$0.52▼$4.26$2.45M1.641.33 million shs921,840 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIPOLipella Pharmaceuticals0.00%+1.85%-0.08%-79.90%-82.03%PBLAPanbela Therapeutics0.00%-5.00%-5.00%-47.20%-55.88%SRNESorrento Therapeutics0.00%-38.33%+146.67%+76.19%-38.33%VRAXVirax Biolabs Group0.00%-6.73%-28.39%-42.26%-85.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIPOLipella Pharmaceuticals$0.60+1.7%$0.68$0.55▼$7.31$2.73M-0.1832,908 shs615 shsPBLAPanbela Therapeutics$0.15$0.17$0.01▼$0.47$728K1.3316,136 shsN/ASRNESorrento Therapeutics$0.00+2.8%$0.00$0.00▼$0.10$1.99M1.08122,404 shs36,874 shsVRAXVirax Biolabs Group$0.57-6.9%$0.81$0.52▼$4.26$2.45M1.641.33 million shs921,840 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIPOLipella Pharmaceuticals0.00%+1.85%-0.08%-79.90%-82.03%PBLAPanbela Therapeutics0.00%-5.00%-5.00%-47.20%-55.88%SRNESorrento Therapeutics0.00%-38.33%+146.67%+76.19%-38.33%VRAXVirax Biolabs Group0.00%-6.73%-28.39%-42.26%-85.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIPOLipella Pharmaceuticals 0.00N/AN/AN/APBLAPanbela Therapeutics 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/AVRAXVirax Biolabs Group 3.00Buy$3.00430.97% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIPOLipella Pharmaceuticals$536.36K5.18N/AN/A$1.59 per share0.38PBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/ASRNESorrento Therapeutics$60.32M0.03N/AN/AN/A∞VRAXVirax Biolabs Group$10K245.21N/AN/A$1.26 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIPOLipella Pharmaceuticals-$5.02M-$3.43N/A∞N/A-988.83%-224.08%-172.88%N/APBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%11/12/2025 (Estimated)SRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/AVRAXVirax Biolabs Group-$6.06MN/A0.00∞N/AN/AN/AN/A10/1/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLIPOLipella PharmaceuticalsN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIPOLipella PharmaceuticalsN/A6.216.21PBLAPanbela TherapeuticsN/A0.260.26SRNESorrento TherapeuticsN/AN/AN/AVRAXVirax Biolabs GroupN/A7.277.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIPOLipella Pharmaceuticals74.31%PBLAPanbela Therapeutics4.37%SRNESorrento Therapeutics0.02%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipLIPOLipella Pharmaceuticals32.11%PBLAPanbela Therapeutics0.01%SRNESorrento Therapeutics2.60%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIPOLipella Pharmaceuticals44.62 million3.03 millionNot OptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionablePBLA, SRNE, LIPO, and VRAX HeadlinesRecent News About These CompaniesVirax Biolabs Group Limited (NASDAQ:VRAX) Short Interest UpdateSeptember 6 at 2:43 AM | americanbankingnews.comVirax Biolabs (VRAX) Falls 18% on Lack of LeadsAugust 27, 2025 | insidermonkey.comVirax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 27, 2025 | finanznachrichten.deVirax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 26, 2025 | prnewswire.comVirax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial StrategyJuly 29, 2025 | prnewswire.comVirax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...July 22, 2025 | finance.yahoo.comVirax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 20, 2025 | finanznachrichten.deVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 18, 2025 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy RecommendationMarch 31, 2025 | msn.comVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy RatingMarch 31, 2025 | benzinga.comVirax Biolabs Launches Clinical Study on T Cell DysfunctionMarch 18, 2025 | msn.comVirax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection SyndromesMarch 18, 2025 | prnewswire.comVirax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation MeetingMarch 13, 2025 | prnewswire.comVirax Biolabs to Present at 19th World Immune Regulation MeetingMarch 5, 2025 | prnewswire.comVirax Biolabs Aligns with US Health Department on Vaccine TransparencyFebruary 25, 2025 | tipranks.comVirax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine EfficacyFebruary 25, 2025 | prnewswire.comCosmos Health expands distribution of Avian Influenza kitsJanuary 23, 2025 | msn.comCosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and KuwaitJanuary 23, 2025 | accessnewswire.comACosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC CountriesJanuary 13, 2025 | accesswire.comAVirax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?December 19, 2024 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBLA, SRNE, LIPO, and VRAX Company DescriptionsLipella Pharmaceuticals NASDAQ:LIPO$0.60 +0.01 (+1.69%) As of 09/5/2025 01:13 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Panbela Therapeutics NASDAQ:PBLA$0.15 0.00 (0.00%) As of 09/5/2025Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Sorrento Therapeutics NASDAQ:SRNE$0.0037 +0.00 (+2.78%) As of 09/5/2025 03:53 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.Virax Biolabs Group NASDAQ:VRAX$0.56 -0.04 (-6.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.56 0.00 (-0.35%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
